 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis |
| Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi |
|
Intest Res. 2021;19(4):448-460. Published online August 18, 2020 DOI: https://doi.org/10.5217/ir.2020.00026 |
|
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis Intestinal Research. 2021;19(4):448-460  Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use Drugs & Therapy Perspectives. 2021;37(12):563-572 Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(10):979-979 Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease BioDrugs. 2014;29(1):57-67 P427 Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial Journal of Crohn's and Colitis. 2021;15(Supplement_1):S431-S432 Cost-Effectiveness of Vedolizumab for the Treatment of Adult Patients with Moderately-to-Severely Active Ulcerative Colitis in Russia Value in Health. 2017;20(9):A635 631 A Multi-Center Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Patients With Moderately-Severely Active Ulcerative Colitis Gastroenterology. 2016;150(4):S132 Erratum to: Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease BioDrugs. 2015;29(1):73-73 Safety and Efficacy of a New 3.3g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Yearbook of Gastroenterology. 2009;2009:110-111 Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Gastroenterology. 2022;162(7):S-602 |
